BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-4.41%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.21B
AUM Growth
+$6.21B
(-11%)
Cap. Flow
-$226M
Cap. Flow
% of AUM
-3.64%
Top 10 Holdings %
Top 10 Hldgs %
40.63%
Holding
166
New
10
Increased
37
Reduced
80
Closed
12
Top Buys
| 1 |
Elevance Health
ELV
|
$31.1M |
| 2 |
UnitedHealth
UNH
|
$24.2M |
| 3 |
Cigna
CI
|
$21.5M |
| 4 |
Humana
HUM
|
$20.8M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$10.5M |
Top Sells
| 1 |
MTEM
Molecular Templates, Inc.
MTEM
|
$64.5M |
| 2 |
Medtronic
MDT
|
$60.3M |
| 3 |
Inspire Medical Systems
INSP
|
$56.9M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$32.8M |
| 5 |
Charles River Laboratories
CRL
|
$16.7M |
Sector Composition
| 1 | Healthcare | 99.13% |
| 2 | Industrials | 0.77% |
| 3 | Energy | 0.04% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$43.6B
| $448M | 7.22% | 911,530 -11,754 | -1% | -$5.78M |
|
2
Ionis Pharmaceuticals
IONS
$6.79B
| $419M | 6.75% | 9,233,700 -146,600 | -2% | -$6.65M |
|
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $349M | 5.62% | 1,002,735 -94,431 | -9% | -$32.8M |
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $291M | 4.68% | 2,583,550 -29,250 | -1% | -$3.29M |
|
5
Intuitive Surgical
ISRG
$170B
| $242M | 3.9% | 828,999 -13,225 | -2% | -$3.87M |
|
|
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $165M | 2.66% | 3,170,250 -31,550 | -1% | -$1.64M |
|
7
Alnylam Pharmaceuticals
ALNY
$58.5B
| $158M | 2.55% | 894,345 -5,305 | -0.6% | -$940K |
|
8
Moderna
MRNA
$9.37B
| $154M | 2.49% | 1,495,325 -29,734 | -2% | -$3.07M |
|
9
Abbott
ABT
$231B
| $151M | 2.44% | 1,560,968 -85,533 | -5% | -$8.28M |
|
10
Incyte
INCY
$16.5B
| $144M | 2.32% | 2,491,450 -149,315 | -6% | -$8.63M |
|
11
Boston Scientific
BSX
$156B
| $140M | 2.25% | 2,646,295 -15,157 | -0.6% | -$800K |
|
12
Revolution Medicines
RVMD
$7.1B
| $131M | 2.11% | 4,721,500 -24,500 | -0.5% | -$678K |
|
|
13
UnitedHealth
UNH
$281B
| $130M | 2.1% | 258,205 +48,078 | +23% | +$24.2M |
|
14
Stryker
SYK
$150B
| $130M | 2.09% | 475,613 -1,333 | -0.3% | -$364K |
|
|
AXNX
15
DELISTED
Axonics, Inc. Common Stock
AXNX
| $126M | 2.04% | 2,252,851 +29,433 | +1% | +$1.65M |
|
16
Evolent Health
EVH
$1.12B
| $100M | 1.61% | 3,677,115 +228,793 | +7% | +$6.23M |
|
17
Agios Pharmaceuticals
AGIO
$2.19B
| $99.3M | 1.6% | 4,013,500 | – | – |
|
|
18
Humana
HUM
$36.5B
| $82.7M | 1.33% | 170,046 +42,673 | +34% | +$20.8M |
|
19
Insmed
INSM
$28.8B
| $79.9M | 1.29% | 3,162,735 -138,176 | -4% | -$3.49M |
|
20
Becton Dickinson
BDX
$55.3B
| $78.7M | 1.27% | 304,230 -33,493 | -10% | -$8.66M |
|
21
Exact Sciences
EXAS
$8.98B
| $76.4M | 1.23% | 1,119,819 +113,047 | +11% | +$7.71M |
|
|
22
Elevance Health
ELV
$71.8B
| $75.7M | 1.22% | 173,887 +71,434 | +70% | +$31.1M |
|
23
Option Care Health
OPCH
$4.65B
| $73.9M | 1.19% | 2,284,293 -3,330 | -0.1% | -$108K |
|
|
SAGE
24
DELISTED
Sage Therapeutics
SAGE
| $72.3M | 1.16% | 3,513,351 +398,976 | +13% | +$8.21M |
|
25
Edwards Lifesciences
EW
$47.8B
| $71M | 1.14% | 1,025,457 -12,635 | -1% | -$875K |
|